[18F]FAPI-74

DRUG7 trials

Sponsors

Turku University Hospital, Varsinais-Suomen hyvinvointialue, National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI)

Conditions

Acute Lung InjuryAllogeneic Stem Cell TransplantationBladder CancerCardiovascular DiseasesCholangiocarcinomaColon cancerGastric CancerGastric cancer

Phase 2

Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?

Not yet recruitingCTIS2024-511104-16-00

Turku University HospitalProstate cancer

Target: 40Updated: 2024-02-28

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

RecruitingNCT06503146

National Cancer Institute (NCI)Bladder Cancer, Cholangiocarcinoma, Gastric Cancer +7

Start: 2025-09-09End: 2030-06-01Target: 320Updated: 2026-05-19

Diagnostic efficacy of 18F-FAPI-74 PET/CT in patients with colon cancer

Not yet recruitingCTIS2024-510651-35-00

Turku University HospitalColon cancer

Target: 100Updated: 2024-08-20

Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Pancreatic Cancer

Not yet recruitingCTIS2023-510208-39-00

Turku University HospitalPancreatic cancer

Target: 100Updated: 2024-08-20

The Expression of Fibroblast Activation Protein in Patients with Non-Small Cell Lung Cancer Patients

Not yet recruitingCTIS2025-523965-97-00

Turku University HospitalNon small cell lung cancer

Target: 60Updated: 2025-12-16

Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer

Not yet recruitingCTIS2026-526494-42-00

Varsinais-Suomen hyvinvointialueGastric cancer

Target: 80Updated: 2026-06-05

Phase 3

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

RecruitingNCT07613099

National Heart, Lung, and Blood Institute (NHLBI)Acute Lung Injury, Allogeneic Stem Cell Transplantation, Cardiovascular Diseases +3

Start: 2026-09-23End: 2033-05-26Target: 210Updated: 2026-09-18